Delix Raises $100M Series C to Take a Non-Hallucinogenic Neuroplastogen into Phase 2b for Depression
- Delix closed an oversubscribed $100M Series C, with J&J's venture arm among the investors.
- Proceeds fund a placebo-controlled Phase 2b of zalsupindole (DLX-001), an oral neuroplastogen, in recurrent major depressive disorder, expected to start in the first half of 2027.
- In a Phase 1b, depression scores fell by about half within eight days with no hallucinatory or dissociative effects reported.
💡 Points Based on public reports
The pitch is psychedelic-like speed without the supervised-session overhead, which is exactly what Compass and Usona's pending psilocybin filings make costly to run. Delix's open question is durability: a one-week course and an eight-day readout say little about relapse, and the placebo response in depression is notoriously large. Phase 2b is where the premium will be earned or lost.
📰 Source · Fierce Biotech ↗ J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression